The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients

Transplantation

Volumn 64, Issue 4, 1997, Pages 604-607

  Irish, Ashley B ^a   Green, Fiona R ^b   Gray, Derek W R ^a   Morris, Peter J ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; FEMALE; GENETIC RISK; GENOTYPE; HEART INFARCTION; HETEROZYGOSITY; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; FACTOR V; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; PREVALENCE; RISK FACTORS; THROMBOPHLEBITIS;

EID: 0030884671     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199708270-00010     Document Type: Article

References (22)

1. Vanrenterghem Y, Roels L, Lerut T, et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985; 1: 999.
2. Jones RM, Murie JA, Ting A, Dunhill MS, Morris PJ. Renal vascular thrombosis of cadaveric renal allografts in patients receiving cyclosporine, azathioprine and prednisolone triple therapy. Clin Transplant 1988; 2: 124.
3. Mahony JF, Caterson RJ, Pollock CA, Jones M, Waugh DA, Sheil AGR. Coronary artery disease is the major late complication of successful cadaveric renal transplantation. Clin Transplant 1990; 4: 129.
4. Gray DWR. Vascular and lymphatic complications after renal transplantation. In: Morris PJ, ed. Kidney transplantation, 4th ed. Philadelphia: W. B. Saunders Company, 1994: 314.
5. Allen RD, Michie CA, Murie JA, Morris PJ. Deep venous thrombosis after renal transplantation. Surg Gynecol Obstet 1987; 164: 137.
6. Cohen H, Neild GH, Mackie IJ, Machin SJ. Persistent decreased fibrinolytic activity in cyclosporin-treated renal allograft recipients. Fibrinolysis 1988; 2: 197.
7. Ibels LS, Stewart JH, Mahony JF, Neale FC, Sheil AR. Occlusive arterial disease in uraemic and haemodialysis patients and renal transplant recipients. Q J Med 1977; 46: 197.
8. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330(8): 517.
9. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64.
10. Bertina RM, Reitsma PH, Rosendaal F, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74(1): 449.
11. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of the factor V Leiden mutation. Lancet 1994; 344: 1453.
12. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912.
13. März W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995; 345: 526.
14. Talmud P, Tybjaerg-Hansen A, Bhatnagar D, et al. Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. Atherosclerosis 1991; 89: 137.
15. Dahlbäck B. New molecular insights into the genetics of thrombophilia: resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995; 74(1): 139.
16. Garcia-Maldonaldo M, Kaufman CE, Comp PC. Decrease in endothelial cell-dependent protein C activation induced by thrombomodulin by treatment with cyclosporine. Transplantation 1991; 51(3): 701.
17. Remuzzi G, Schieppati A, Ruggenenti P, Bertani T. Collagen, vascular, haematologic, and vasculitis-related renal diseases. In: Schrier RW, Gottschalk CW, eds. Diseases of the kidney, 5th ed, Vol. 2. Boston: Little Brown and Company, 1992: 2063.
18. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of The Northwick Park Heart Study. Lancet 1986; 2: 533.
19. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. Thromb Haemost 1994; 71(6): 719.
20. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995; 74(1): 71.
21. Green F, Hamsten A, Blomback M, Humphries S. The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 70(6): 915.
22. Dawson S, Wiman B, Hamsten A, Green F, Humphries S, Henney A. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268(15): 10739.